{"id":23164,"date":"2022-02-03T15:18:41","date_gmt":"2022-02-03T14:18:41","guid":{"rendered":"https:\/\/kymos.com\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/"},"modified":"2025-08-07T20:33:49","modified_gmt":"2025-08-07T18:33:49","slug":"acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos","status":"publish","type":"post","link":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/","title":{"rendered":"\u00c1cidos nucleicos: de perdedores biol\u00f3gicos a l\u00edderes biotecnol\u00f3gicos"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><span style=\"font-size: 14pt;\">El <a href=\"https:\/\/kymos.com\/es\/servicios\/servicios-preclinicos-y-clinicos\/bioanalisis-de-acidos-nucleicos\/\" data-wpel-link=\"internal\">bioan\u00e1lisis de \u00e1cidos nucleicos<\/a> , especialmente en matrices biol\u00f3gicas, es uno de los servicios m\u00e1s recientes que ofrece el Grupo Kymos y se lleva a cabo en su filial alemana Prolytic. Maria Fauth, jefa del Departamento de Oligonucle\u00f3tidos, ha dedicado toda su carrera acad\u00e9mica y empresarial a la investigaci\u00f3n y el an\u00e1lisis de \u00e1cidos nucleicos. Ella y la Dra. Janine Lossie, de OMEICOS Therapeutics, comparten sus perspectivas sobre este prometedor campo:  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u201cYa de estudiante me fascinaban los oligonucle\u00f3tidos, especialmente los miARN\u201d, comienza Maria Fauth. \u201cDurante mucho tiempo, la comunidad cient\u00edfica los consider\u00f3 mol\u00e9culas biol\u00f3gicamente in\u00fatiles, hasta que se descubri\u00f3 que tienen funciones reguladoras cruciales. Desde entonces, la importancia de los \u00e1cidos nucleicos ha ido en aumento en el sector sanitario, y con el inicio del brote de COVID-19, las vacunas de ARNm han cobrado gran importancia en la concienciaci\u00f3n p\u00fablica\u201d.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u201cEsto representa un gran reconocimiento para nuestro equipo, que lleva d\u00e9cadas estudiando y trabajando con ARN, pero al mismo tiempo representa un gran reto\u201d, afirma la Sra. Fauth. \u201cEl \u00e9xito de las vacunas de ARNm ha generado mucha atenci\u00f3n, pero tambi\u00e9n ha puesto de manifiesto que la investigaci\u00f3n de f\u00e1rmacos nucle\u00f3tidos solo puede realizarse con an\u00e1lisis s\u00f3lidos. Por ello, hemos centrado nuestros esfuerzos en el desarrollo y la validaci\u00f3n de m\u00e9todos estandarizados y reproducibles para la cuantificaci\u00f3n de una gran variedad de \u00e1cidos nucleicos\u201d.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">El an\u00e1lisis de biomarcadores basados en \u00e1cidos nucleicos o f\u00e1rmacos terap\u00e9uticos requiere enfoques bioanal\u00edticos espec\u00edficos debido a sus diferentes niveles de concentraci\u00f3n: para la cuantificaci\u00f3n de oligonucle\u00f3tidos terap\u00e9uticos, los m\u00e9todos ELISA o LC-MS\/MS son los m\u00e1s adecuados, seg\u00fan la sensibilidad requerida. Sin embargo, estas tecnolog\u00edas son insuficientes para biomarcadores a concentraciones atmolares, donde la tecnolog\u00eda qPCR en tiempo real se convierte en el est\u00e1ndar de oro. Maria Fauth profundiza:  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Nos complace enormemente poder ofrecer todos estos m\u00e9todos (ELISA de hibridaci\u00f3n, LC-MS\/MS y qPCR) en condiciones GLP en Prolytic. Con estas tecnolog\u00edas, no solo podemos cuantificar biomarcadores o terapias basadas en ADN y ARNm, sino tambi\u00e9n otras herramientas terap\u00e9uticas emergentes como los apt\u00e1meros o los antagomiRs, que se emplean para modificar la expresi\u00f3n g\u00e9nica e influir en la progresi\u00f3n de enfermedades. De este modo, cubrimos un amplio espectro de an\u00e1lisis de oligonucle\u00f3tidos, algo que nuestros clientes valoran enormemente\u00bb, explica con satisfacci\u00f3n.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">De hecho, muchas empresas farmac\u00e9uticas globales y peque\u00f1as empresas biotecnol\u00f3gicas innovadoras est\u00e1n cada vez m\u00e1s interesadas en la investigaci\u00f3n de \u00e1cidos nucleicos. La Dra. Janine Lossie, jefa de farmacolog\u00eda <em>in vivo<\/em> en OMEICOS Therapeutics y clienta de Prolytic desde hace muchos a\u00f1os, tambi\u00e9n ve el gran beneficio de los m\u00e9todos anal\u00edticos validados para \u00e1cidos nucleicos: <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Prolytic nos ha acompa\u00f1ado durante todo el proceso de desarrollo de nuestra mol\u00e9cula peque\u00f1a OMT-28, pionera en su clase. Nos complace enormemente saber que Prolytic tambi\u00e9n puede medir \u00e1cidos nucleicos bajo BPL, ya que vemos el potencial de utilizarlos como biomarcadores para evaluar la eficacia de nuestros f\u00e1rmacos en el futuro. Confiamos en la competencia del equipo de Maria Fauth y estamos seguros de que nuestra colaboraci\u00f3n en este \u00e1mbito seguir\u00e1 creciendo.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">La determinaci\u00f3n de biomarcadores de \u00e1cidos nucleicos seg\u00fan las BPL se recomienda actualmente, pero no es un requisito obligatorio. No obstante, Maria Fauth tiene la firme convicci\u00f3n de que, dado que tanto la FDA como la EMA prestan cada vez m\u00e1s atenci\u00f3n a los biomarcadores basados en \u00e1cidos nucleicos, es solo cuesti\u00f3n de tiempo que se introduzcan las directrices correspondientes. Su equipo se ha preparado en consecuencia:  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00abDado que experimentamos una creciente demanda, hemos establecido un sistema de procesamiento automatizado de \u00e1cidos nucleicos basado en latidos magn\u00e9ticos e instalado un instrumento de qPCR multiplex\u00bb, afirma la Sra. Fauth. \u00abComo resultado, ahora podemos alcanzar rendimientos mucho mayores y estamos preparados para satisfacer las necesidades futuras de nuestros clientes\u00bb. A continuaci\u00f3n, Maria Fauth concluye con las siguientes reflexiones: \u00abEs una satisfacci\u00f3n personal que la disciplina cient\u00edfica a la que he dedicado a\u00f1os de mi carrera est\u00e9 experimentando un desarrollo tan espectacular. Mi equipo y yo apreciamos enormemente el esp\u00edritu innovador de Prolytic y Kymos y estamos muy ilusionados con todos esos interesantes proyectos que est\u00e1n por venir\u00bb.   <\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 14pt;\">OMEICOS Therapeutics es una compa\u00f1\u00eda biofarmac\u00e9utica que desarrolla terapias de mol\u00e9culas peque\u00f1as de primera clase para la prevenci\u00f3n y el tratamiento de enfermedades cardiovasculares y otras enfermedades asociadas con la inflamaci\u00f3n y la disfunci\u00f3n mitocondrial. Para m\u00e1s informaci\u00f3n, visite <a href=\"http:\/\/www.omeicos.com\" data-wpel-link=\"external\">www.omeicos.com<\/a> o cont\u00e1ctenos en <a href=\"mailto:info@omeicos.com\" data-wpel-link=\"internal\">info@omeicos.com<\/a> . <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":21953,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[181],"tags":[62],"class_list":["post-23164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalisis","tag-joan"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c1cidos nucleicos: \u00bfbiomarcadores o f\u00e1rmacos terap\u00e9uticos? | Grupo Kymos<\/title>\n<meta name=\"description\" content=\"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadores basados en \u00e1cidos nucleicos y f\u00e1rmacos terap\u00e9uticos. \u00a1Descubre m\u00e1s!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c1cidos nucleicos: \u00bfbiomarcadores o f\u00e1rmacos terap\u00e9uticos? | Grupo Kymos\" \/>\n<meta property=\"og:description\" content=\"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadores basados en \u00e1cidos nucleicos y f\u00e1rmacos terap\u00e9uticos. \u00a1Descubre m\u00e1s!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-03T14:18:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T18:33:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1292\" \/>\n\t<meta property=\"og:image:height\" content=\"714\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"\u00c1cidos nucleicos: de perdedores biol\u00f3gicos a l\u00edderes biotecnol\u00f3gicos\",\"datePublished\":\"2022-02-03T14:18:41+00:00\",\"dateModified\":\"2025-08-07T18:33:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/\"},\"wordCount\":944,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"keywords\":[\"joan\"],\"articleSection\":[\"Bioan\u00e1lisis\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/\",\"name\":\"\u00c1cidos nucleicos: \u00bfbiomarcadores o f\u00e1rmacos terap\u00e9uticos? | Grupo Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"datePublished\":\"2022-02-03T14:18:41+00:00\",\"dateModified\":\"2025-08-07T18:33:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadores basados en \u00e1cidos nucleicos y f\u00e1rmacos terap\u00e9uticos. \u00a1Descubre m\u00e1s!\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"width\":1292,\"height\":714,\"caption\":\"Nucleic Acids\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c1cidos nucleicos: de perdedores biol\u00f3gicos a l\u00edderes biotecnol\u00f3gicos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c1cidos nucleicos: \u00bfbiomarcadores o f\u00e1rmacos terap\u00e9uticos? | Grupo Kymos","description":"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadores basados en \u00e1cidos nucleicos y f\u00e1rmacos terap\u00e9uticos. \u00a1Descubre m\u00e1s!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/","og_locale":"es_ES","og_type":"article","og_title":"\u00c1cidos nucleicos: \u00bfbiomarcadores o f\u00e1rmacos terap\u00e9uticos? | Grupo Kymos","og_description":"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadores basados en \u00e1cidos nucleicos y f\u00e1rmacos terap\u00e9uticos. \u00a1Descubre m\u00e1s!","og_url":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/","og_site_name":"Kymos","article_published_time":"2022-02-03T14:18:41+00:00","article_modified_time":"2025-08-07T18:33:49+00:00","og_image":[{"width":1292,"height":714,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrito por":"Joan Puig de Dou","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"\u00c1cidos nucleicos: de perdedores biol\u00f3gicos a l\u00edderes biotecnol\u00f3gicos","datePublished":"2022-02-03T14:18:41+00:00","dateModified":"2025-08-07T18:33:49+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/"},"wordCount":944,"image":{"@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","keywords":["joan"],"articleSection":["Bioan\u00e1lisis"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/","url":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/","name":"\u00c1cidos nucleicos: \u00bfbiomarcadores o f\u00e1rmacos terap\u00e9uticos? | Grupo Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","datePublished":"2022-02-03T14:18:41+00:00","dateModified":"2025-08-07T18:33:49+00:00","author":{"@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadores basados en \u00e1cidos nucleicos y f\u00e1rmacos terap\u00e9uticos. \u00a1Descubre m\u00e1s!","breadcrumb":{"@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","width":1292,"height":714,"caption":"Nucleic Acids"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/es\/news\/acidos-nucleicos-de-perdedores-biologicos-a-lideres-biotecnologicos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/es\/"},{"@type":"ListItem","position":2,"name":"\u00c1cidos nucleicos: de perdedores biol\u00f3gicos a l\u00edderes biotecnol\u00f3gicos"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/es\/#website","url":"https:\/\/kymos.com\/es\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/es\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/comments?post=23164"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23164\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/media\/21953"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/media?parent=23164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/categories?post=23164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/tags?post=23164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}